205 related articles for article (PubMed ID: 11320901)
41. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
42. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis.
Buhr T; Hebeda K; Kaloutsi V; Porwit A; Van der Walt J; Kreipe H
Haematologica; 2012 Mar; 97(3):360-5. PubMed ID: 22058215
[TBL] [Abstract][Full Text] [Related]
43. A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2006 Mar; 47(3):381-96. PubMed ID: 16396760
[TBL] [Abstract][Full Text] [Related]
44. Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis.
Brousseau M; Parot-Schinkel E; Moles MP; Boyer F; Hunault M; Rousselet MC
Histopathology; 2010 May; 56(6):758-67. PubMed ID: 20546341
[TBL] [Abstract][Full Text] [Related]
45. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
46. Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification.
Kvasnicka HM; Thiele J
Pathobiology; 2007; 74(2):63-71. PubMed ID: 17587877
[TBL] [Abstract][Full Text] [Related]
47. [Investigation and treatment of prefibrotic/early primary myelofibrosis. A case study].
Magyari F; Bedekovics J; Décsy J; Ilonczai P; Illés Á; Simon Z
Orv Hetil; 2018 Apr; 159(15):603-609. PubMed ID: 29631428
[TBL] [Abstract][Full Text] [Related]
48. Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl.
Thiele J; Kvasnicka HM; Vardiman J
Best Pract Res Clin Haematol; 2006; 19(3):413-37. PubMed ID: 16781481
[TBL] [Abstract][Full Text] [Related]
49. Value of bone marrow biopsy in the diagnosis of essential thrombocythemia.
Florena AM; Tripodo C; Iannitto E; Porcasi R; Ingrao S; Franco V
Haematologica; 2004 Aug; 89(8):911-9. PubMed ID: 15339673
[TBL] [Abstract][Full Text] [Related]
50. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
[TBL] [Abstract][Full Text] [Related]
51. Acute panmyelosis with myelofibrosis.
Thiele J; Kvasnicka HM; Schmitt-Graeff A
Leuk Lymphoma; 2004 Apr; 45(4):681-7. PubMed ID: 15160939
[TBL] [Abstract][Full Text] [Related]
52. Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients.
Thiele J; Kvasnicka HM; Beelen DW; Leder LD; Schaefer UW
Histol Histopathol; 2001 Jan; 16(1):213-26. PubMed ID: 11193198
[TBL] [Abstract][Full Text] [Related]
53. Hematopathologic findings in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM
Semin Oncol; 2005 Aug; 32(4):380-94. PubMed ID: 16202684
[TBL] [Abstract][Full Text] [Related]
54. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.
Michiels JJ; Juvonen E
Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350
[TBL] [Abstract][Full Text] [Related]
55. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
56. Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Schmitt-Graeff A; Diehl V
Histopathology; 2003 Nov; 43(5):470-9. PubMed ID: 14636273
[TBL] [Abstract][Full Text] [Related]
57. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
58. [Diagnosis of chronic myeloproliferative diseases based on bone marrow biopsy].
Matolcsy A; Kónya T; Wéber E
Orv Hetil; 1992 Jun; 133(26):1617-20, 1625-6. PubMed ID: 1614699
[TBL] [Abstract][Full Text] [Related]
59. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
Barosi G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
[TBL] [Abstract][Full Text] [Related]
60. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
Tovar-Bobadilla JL; Ortiz-Hidalgo C
Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]